Cancer Immunotherapy in India: A Deep Patent Base, Thin Startup Activity

What it is

Cancer immunotherapy harnesses the body’s own immune system to find and destroy malignant cells. Unlike chemotherapy or radiation, which attack cancer directly, immunotherapy trains or boosts immune cells to recognize and eliminate tumors that would otherwise evade detection.

Key approaches include checkpoint inhibitors that release brakes on T cells, adoptive cell therapies like CAR-T that engineer a patient’s own immune cells to target cancer, and monoclonal antibodies that flag cancer cells for destruction. Current treatments aim to extend survival rather than cure, but they have transformed outcomes in several hard-to-treat cancers.

The value chain

• Upstream – Drug discovery & preclinical development: identifying immune-oncology targets and designing therapeutic candidates. High IP defensibility and value sit here.
• Midstream – Clinical trials: specialized patient recruitment, cold chain logistics, and patient-centric services. Manufacturing & CDMO: production of biologics, cell therapies, and monoclonal antibodies, often outsourced. Logistics: personalized, just-in-time supply chains for cell therapies.
• Downstream – Administration & end use: treatment delivered in hospitals and clinics, which held 71.4% of the global market in 2025 (Grand View Research). Margins are thinner but volume is high.

Where it's heading

• Global market valued at USD 153.3 billion in 2025, growing at 9.0% CAGR through 2033 (Grand View Research).
• Monoclonal antibodies remain the dominant product segment (61.6% share in 2025), while lung cancer leads applications (18.1% share).
• Key trends: combination therapy regimens, next-generation checkpoint inhibitors, and expansion of CAR-T cell therapies into solid tumors.
• India’s market is nascent but likely to mirror global growth as regulatory pathways evolve and local manufacturing capabilities emerge.

The opportunity in India

Our data reveals a stark gap: 471 patents mapped to cancer immunotherapy, yet only one patent-holding startup appears—Zumutor Biologics (Bengaluru). Just one deep-tech company in our dataset, THRAFFORD LIFESCIENCE (Gautam Buddha Nagar), explicitly references the technology. This suggests a large pool of untapped IP, likely from academic institutions and large pharma, with minimal startup commercialization.

The broader health-life-sciences sector has attracted $2.6 billion in funding across 973 companies, indicating ample capital that could be channeled into immunotherapy ventures. White space exists in licensing existing patents, building CAR-T manufacturing capacity, and developing India-specific affordable immunotherapies.

India signal: patents, startups, capital

Patents matched: 471. Momentum is indeterminate due to India’s ~18-month patent confidentiality window; the latest filings are not yet public, so no trend can be inferred.

Patent-holding startups: 1 — Zumutor Biologics Pvt Ltd (Bengaluru) with a single patent. Companies in our data: 1 — THRAFFORD LIFESCIENCE PRIVATE LIMITED (Gautam Buddha Nagar). Both figures are lower bounds; other firms may operate without patents or under different descriptors.

Sector funding (health-life-sciences): $2575.2M total raised across 973 companies, median $1.0M. Notable funded players include Enveda ($517M), Qure.ai ($130M), Atonarp ($111M), SigTuple ($54.7M), Pandorum Technologies ($52.1M), and Vivimed Labs ($50M). None are pure-play cancer immunotherapy startups, underscoring the gap.

In our data

Sources

• Immunotherapy for Cancer ↗
• What Is Immunotherapy? ↗
• Immunotherapy for Cancer: How It Works, Benefits and ... ↗
• Delivering the Full Value Chain for Oncology Clinical Trials ↗
• Personalized Supply Chains for Cell Therapies ↗
• Who are the Top Companies in the North America Cancer ... ↗
• Cancer Immunotherapy Market Size Report, 2026-2033 ↗
• U.S. Cancer Immunotherapy Market Size, Industry Report, 2035 ↗